Opinion

Video

Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC

Author(s):

Edgardo S. Santos, MD, FACP, FCCP,Martin Dietrich, MD, PhD

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

Related Videos
4 experts are featured in this series.
Related Content
Alexander Watson, MD, DPhil, FRCPC
January 23rd 2025

Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC

Alec Watson, MD, thoracic oncology fellow, School of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus
January 13th 2025

Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD

TKIs in Second-Line HER2-Mutant NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 21st 2025

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Limertinib for EGFR T790M+ NSCLC | Image Credit: © catalin – stock.adobe.com
January 17th 2025

Limertinib Wins Approval in China for EGFR T790M+ NSCLC

Alison Schram, MD
January 16th 2025

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer